Abstract Library

#679 Malignant Pheocromocytoma: Rare, Aggressive, but Easily Neglected

Introduction: Pheocromocytomas are rare neuroendocrine tumors of which only 10% present metastatic disease.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Ribeiro C

Authors: Ribeiro C, Patrício C, Gaspar C, Pereira R, Silva F,

Keywords: malignant pheocromocytoma, cyanosis, methanephrines, adrenergic crisis ,

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma

Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: De Marinis L

Authors: Lugli F, Fusco A, Bianchi A, Iacovazzo D, Mormando M,

Keywords: malignant pheochromocytoma, 18F-DOPA-PET, MIBG,